Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis

Park, Sun; Huang, Wei; Jin, Mingji; Wang, Qiming; Fan, Bo; Kang, Lin; Gao, Zhonggao

doi:10.2147/ijn.s105427

Cited by 73 publications

(44 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, poly (ethylene glycol)modified chitosan NPs were synthesized to encapsulate and deliver small interfering RNA (siRNA). The siRNA loaded NPs showed 4T1 cell inhibition both in vitro and in vivo ensuring its efficacy in reduction of tumor growth and metastasis (Sun et al, 2016). Wan et al developed the lapatinib-loaded human serum albumin NPs that exhibited a core-shell structure with stealth properties preventing brain metastasis from triple-negative breast cancer (Wan et al, 2016).…”

Section: Breast Cancermentioning

confidence: 99%

Cancer Chemoprevention Using Nanotechnology-Based Approaches

et al. 2020

View full text Add to dashboard Cite

Cancer research in pursuit of better diagnostic and treatment modalities has seen great advances in recent years. However, the incidence rate of cancer is still very high. Almost 40% of women and men are diagnosed with cancer during their lifetime. Such high incidence has not only resulted in high mortality but also severely compromised patient lifestyles, and added a great socioeconomic burden. In view of this, chemoprevention has gained wide attention as a method to reduce cancer incidence and its relapse after treatment. Among various stems of chemoprevention research, nanotechnology-based chemoprevention approaches have established their potential to offer better efficacy and safety. This review summarizes recent advances in nanotechnology-based chemoprevention strategies for various cancers with emphasis on lung and bronchial cancer, colorectal, pancreatic, and breast cancer and highlights the unmet needs in this developing field towards successful clinical translation.

show abstract

Section: Breast Cancermentioning

confidence: 99%

Cancer Chemoprevention Using Nanotechnology-Based Approaches

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thus, there may be some difficulties in adhering to technologies involving siRNA because there are few firms with expertise in their development which delays the approval of drugs. It is difficult to correctly deliver siRNA treatments without the drugs being degraded by nuclease enzymes and without promoting side effects [24]. This technological challenge is also observed in treatments involving cell therapy [25].…”

Section: Clinical Trials Involving Vaccines and New Therapies For Covmentioning

confidence: 99%

Cooperative efforts on developing vaccines and therapies for COVID-19 Cooperative efforts for COVID-19

Basso

Paulo

Porto

et al. 2020

Preprint

View full text Add to dashboard Cite

Health organizations have always sought partnership to join competencies in innovation, even with fierce competition in this sector. In this pandemic moment it is relevant to observe how organizations behave to seek quick and safe answers. The present research analyzes how the cooperation networks were set off considering the clinical trials on therapies and vaccines that were developed specifically to treat or prevent COVID-19. Social Network Analysis technique was used to build cooperation networks and apply metrics that characterize these connections. There was an evaluation of statistics of Strength of cooperation and Unilateral dependence of cooperation that identify the cooperation strength between two organizations, and the dependence of this relations. A total of 415 clinical trial were identified, of which 42% are in cooperation. From organizations that have partnership, firms are the first, followed by universities. We extracted the main categories that concentrate 74% of partnerships in the trials of antibody, and vaccine. Several organizations cooperate in multiple categories of trials, evidencing the efforts to focus on different strategies to treat the disease. We found high strength of cooperation and an assimetryc dependency between partners, which can be assigned to specialized models of partnership and it occurs in competitive enviroments like this pandemic moment. Cooperation were not limited to geographical proximity and the advent of Chinese players can represent a new change in the biotechnological development axis. Finally, the challenge of finding therapeutic or immunological solutions for COVID-19 demonstrates a clear composition of cooperation groups that complement their skills to manage organizational strategies to beat the pandemic. In this new paradigm, there can be partnerships not only in clinical trial but also in pre-competitive technologies development. This experience is expected to change the way of organizations define their R&D strategies and start to adopt more a collaborative innovation model.

show abstract

“…Also, CS could be exploited as an ideal delivery carrier to protect microRNA and other noncoding RNAs from RNase to prevent their degradation and poor penetration. Indeed, related results have demonstrated that PEG‐CS nanoparticles were successfully developed to be safe and efficient vectors for siRNA delivery (Sun et al, 2016). Additionally, it has also been reported that siRNA conjugated CS nanoparticles fabricated with antibody could specifically target M1 macrophages and reduce the expression of iNOS, enhance the functional recovery by inhibiting of the apoptosis in the lesion site of injured spinal cord (Gao and Li, 2017).…”

Section: Sustained Release Of Neurotrophic Factors By Chitosan Complementioning

confidence: 99%

Application of stem cells and chitosan in the repair of spinal cord injury

Zhou

et al. 2019

Intl J of Devlp Neuroscience

View full text Add to dashboard Cite

Cytology and histology obstacles have been the main barriers to multiple tissues injury repair. In search of the most promising treatment strategies for spinal cord injury (SCI), stem cell‐based transplantation coupled with various materials/technologies have been explored extensively to enhance SCI repair. Chitosan (CS) has demonstrated immense potential for widespread application in the form of scaffolds and micro‐particles for SCI repair. The current review summarizes the evidences for stem cell‐based transplantation and CS in SCI repair. Stem cells transplantation, which plays a key role in the repair of SCI, mainly results from its neural differentiation potential and neurotrophic effects. Application of CS enhances the survival of grafted stem cells, upregulates the expression level of neurotrophic factors and heightens the neural differentiation of stem cells as well as the functional recovery of spinal cord. Meanwhile, CS can also be exploited as growth factors/RNA carriers to control the release of regenerating molecules which are beneficial to damage spinal cord repair.

show abstract

Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis

Cited by 73 publications

References 38 publications

Cancer Chemoprevention Using Nanotechnology-Based Approaches

Cancer Chemoprevention Using Nanotechnology-Based Approaches

Cooperative efforts on developing vaccines and therapies for COVID-19 Cooperative efforts for COVID-19

Application of stem cells and chitosan in the repair of spinal cord injury

Contact Info

Product

Resources

About